Ibrutinib, inhibiting the Bruton’s tyrosine kinase (BTK) involved in BCR signaling; in combination with R-CHOP also improve event-free survival of DLBCL patients (115, 116). Here, DDIT3 is linked to diffuse large B-cell lymphoma.